Epcoritamab as Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

被引：0
|
作者：
Dong, Ning [1 ]
Gaballa, Sameh [1 ]
Jain, Michael D. [1 ]
Saeed, Hayder [1 ]
Kareem, Saba [1 ]
Corallo, Salvatore [1 ]
Zhang, Yumeng [1 ]
Shah, Bijal [1 ]
Isenalumhe, Leidy [1 ]
Celeste, Bello [1 ]
Locke, Frederick [1 ]
Sokol, Lubomir [1 ]
Pinilla, Javier [1 ]
Chavez, Julio [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
ABCL; DLBCL; bispecific antibody; epcoritamab; standard of care;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-081
引用
收藏
页码：S456 / S456
页数：1
相关论文
共 50 条
  • [21] Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
    Tomita, Naoto
    Takasaki, Hirotaka
    Fujisawa, Shin
    Miyashita, Kazuho
    Ogusa, Eriko
    Kishimoto, Kumiko
    Matsuura, Shiro
    Sakai, Rika
    Koharazawa, Hideyuki
    Yamamoto, Wataru
    Fujimaki, Katsumichi
    Fujita, Hiroyuki
    Ishii, Yoshimi
    Taguchi, Jun
    Kuwabara, Hideyuki
    Motomura, Shigeki
    Ishigatsubo, Yoshiaki
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2013, 53 (02) : 121 - 125
  • [22] Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
    Tomita, Naoto
    Takasaki, Hirotaka
    Fujisawa, Shin
    Miyashita, Kazuho
    Ogusa, Eriko
    Kishimoto, Kumiko
    Matsuura, Shiro
    Sakai, Rika
    Koharazawa, Hideyuki
    Yamamoto, Wataru
    Fujimaki, Katsumichi
    Fujita, Hiroyuki
    Yamamoto, Yoshimi
    Taguchi, Jun
    Kuwabara, Hideyuki
    Motomura, Shigeki
    Ishigatsubo, Yoshiaki
    BLOOD, 2011, 118 (21) : 708 - 709
  • [23] Epcoritamab plus R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
    Karimi, Yasmin
    Abrisqueta, Pau
    de Vos, Sven
    Nijland, Marcel
    Offner, Fritz
    Osei-Bonsu, Kojo
    Rana, Ali
    Archer, Kimberly G.
    Song, Yaou
    Cordoba, Raul
    Falchi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma
    Izutsu, Koji
    Kumode, Takahiro
    Yuda, Junichiro
    Nagai, Hirokazu
    Mishima, Yuko
    Suehiro, Youko
    Yamamoto, Kazuhito
    Fujisaki, Tomoaki
    Ishitsuka, Kenji
    Ishizawa, Kenichi
    Ikezoe, Takayuki
    Nishikori, Momoko
    Akahane, Daigo
    Fujita, Jiro
    Dinh, Minh
    Soong, David
    Noguchi, Hidehisa
    Buchbjerg, Jeppe Klint
    Favaro, Elena
    Fukuhara, Noriko
    CANCER SCIENCE, 2023, 114 (12) : 4643 - 4653
  • [25] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Bell, Jill A.
    Cherepanov, Dasha
    Revicki, Dennis
    Speck, Rebecca M.
    Swett, Laura
    Stumpo, Kate
    Rong, Yuanxin
    Gordon, Leo I.
    QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
  • [26] Novel subgroup analyses of subcutaneous epcoritamab in patients with relapsed/refractory large B-cell lymphoma
    Lewis, David John
    Lewis, David John
    Thieblemont, Catherine
    Ghesquieres, Herve
    Cheah, Chan Y.
    Clausen, Michael Roost
    Cunningham, David
    Do, Young Rok
    Feldman, Tatyana
    Gasiorowski, Robin
    Jurczak, Wojciech
    Kim, Tae Min
    van der Poel, Marjolein
    Poon, Michelle Limei
    Kilavuz, Nurgul
    Stirner, Mariana Cota
    Soong, David
    Chiu, Christopher W.
    Chen, Menghui
    Sacchi, Mariana
    Elliott, Brian
    Hutchings, Martin
    Lugtenburg, Pieternella
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 11 - 12
  • [27] GENERATING HEALTH-STATE UTILITY VALUES IN PATIENTS TREATED WITH SECOND-LINE SYSTEMIC THERAPY FOR RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)
    Soare, I. A.
    Little, M.
    Klijn, S. L.
    Elsada, A.
    Gibson, A.
    Liu, F. F.
    Becker, F.
    VALUE IN HEALTH, 2023, 26 (12) : S463 - S463
  • [28] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
    Topp, Max S.
    van Meerten, Tom
    Houot, Roch
    Minnema, Monique
    Milpied, Noel
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wermke, Martin
    Song, Kevin
    Avivi, Irit
    Kuruvilla, John
    Duehrsen, Ulrich
    Chu, Rachel
    Zheng, Lianqing
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S101 - S101
  • [29] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care?
    Westin, Jason
    Hagemeister, Fredrick
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2013, 2 (06) : 537 - 540
12345